Pd05-07 Incidence Rates of Metastatic Prostate Cancer at Time of Diagnosis Among Black Men in Nyc − a Breakdown by Age and Geography

You have accessJournal of UrologyDiversity, Equity & Inclusion: Health Equity & Outcomes I (PD05)1 May 2024PD05-07 INCIDENCE RATES OF METASTATIC PROSTATE CANCER AT TIME OF DIAGNOSIS AMONG BLACK MEN IN NYC − A BREAKDOWN BY AGE AND GEOGRAPHY Meenakshi Davuluri, Jialin Mao, Faith Morely, and Kevin Kensler Meenakshi DavuluriMeenakshi Davuluri , Jialin MaoJialin Mao , Faith MorelyFaith Morely , and Kevin KenslerKevin Kensler View All Author Informationhttps://doi.org/10.1097/01.JU.0001008624.07191.ab.07AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract INTRODUCTION AND OBJECTIVE: It is well established that Black men are at 2 times higher risk of getting prostate cancer. The American Urologic Association recommends screening for prostate cancer as early as 40 years of age if there are risk factors present. This study evaluates stage-specific prostate cancer incidence rates by race, age, and borough among men within New York City (NYC) to determine if any disparities exist. METHODS: Utilizing data from the New York State Cancer Registry, we estimated age-standardized stage-specific prostate cancer incidence rates from 2011-2020. Prostate tumors were classified as localized, regional, or metastatic based on SEER summary stage. Incidence rate ratios (IRRs) were estimated to compare rates among non-Hispanic Black (NHB) and non-Hispanic White (NHW) men in NYC by age and borough. RESULTS: From 2011-2020, NHB men had an overall 2.58-fold higher incidence of metastatic disease at time of diagnosis (95% 2.40-2.78) relative to NHW men in NYC. Higher incidence rates of metastatic prostate cancer were seen among NHB men in all boroughs and were highest in the Bronx, followed by Manhattan, Brooklyn, Queens, and Staten Island. In men aged 55-69, IRRs comparing metastatic disease incidence between NHB and NHW men ranged from 2.58 (95% CI 0.95-3.42) in Queens to 4.46 (95% CI 3.42-5.83) in Manhattan (Table 1). These differences were even greater among men<55 years of age, with NHB men in Manhattan (IRR=4.53, 95% CI 1.89-10.74), Queens (IRR=5.27, 95% CI 1.97-16.19), and Brooklyn (IRR=5.54, 95% CI 2.58-13.72) experiencing significantly higher rates of metastatic disease at time of diagnosis compared to NHW men in these same boroughs (Table 1). CONCLUSIONS: NHB men are more likely to be diagnosed with metastatic prostate cancer when compared to NHW men in NYC. The highest relative risk is among young (<55 years) NHB men in Brooklyn. These study findings identify large gaps in prostate cancer screening for a cohort of men whose life expectancy could potentially be extended by earlier diagnosis. These areas of NYC would benefit from focused public health education and screening efforts to mitigate the disparate rates of metastatic prostate cancer diagnosis. Source of Funding: Supported by The Frederick J. and Theresa Dow Wallace Fund of the New York Community Trust © 2024 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 211Issue 5SMay 2024Page: e92 Advertisement Copyright & Permissions© 2024 by American Urological Association Education and Research, Inc.Metrics Author Information Meenakshi Davuluri More articles by this author Jialin Mao More articles by this author Faith Morely More articles by this author Kevin Kensler More articles by this author Expand All Advertisement PDF downloadLoading ...